Ibrutinib does not prevent kidney fibrosis following acute and chronic injury
Abstract Recent studies suggested that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, developed for the treatment of chronic lymphocytic leukemia, may prevent NLRP3 inflammasome activation in macrophages, IL-1β secretion and subsequent development of inflammation and organ fibrosis. The role o...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/2020b7952aae4eb88a1c4a7634ff29e2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|